BioCentury's 10th annual European Iceberg Survey foresees diverging capital needs for private and public clinical-stage companies over the next three years.

Overall, the region's projected financing demand to support operations through the end of 2014 has reached an all-time high of $5.7 billion, up 6% from $5.4 billion in last year's survey (see "Europe's Total Demand").